MicroPort Endovascular MedTech Ltd Cash Flow Conversion Efficiency
MicroPort Endovascular MedTech Ltd cash flow conversion efficiency. Based on the latest financial reports, MicroPort Endovascular MedTech Ltd (688016) has a cash flow conversion efficiency ratio of 0.012x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥46.79 Million ≈ $6.85 Million USD) by net assets (CN¥3.98 Billion ≈ $582.73 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of MicroPort Endovascular MedTech Ltd (2016–2025)
Cash flow conversion efficiency of MicroPort Endovascular MedTech Ltd from 2016 to 2025. This chart illustrates how MicroPort Endovascular MedTech Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 688016 live share price for real-time trading data and today's change.
MicroPort Endovascular MedTech Ltd Cash Flow Conversion Ratio Explained
MicroPort Endovascular MedTech Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
MicroPort Endovascular MedTech Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MicroPort Endovascular MedTech Ltd ranked by their cash flow conversion efficiency. Also see MicroPort Endovascular MedTech Ltd stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
agilon health Inc
NYSE:AGL
|
-0.148x |
|
Bayer Cropscience Limited
NSE:BAYERCROP
|
-0.012x |
|
Usha Martin Limited
NSE:USHAMART
|
0.112x |
|
Telkom
JSE:TKG
|
0.176x |
|
IRPC Public Company Limited
BK:IRPC
|
0.214x |
|
Shenzhen Colibri Technologies Co Ltd
SHE:002957
|
0.026x |
|
China Aluminum International Engineering Corp Ltd
SHG:601068
|
0.031x |
|
AKSO HEALTH GR. (SPADR)/3
F:8HX
|
N/A |
Annual Cash Flow Conversion Efficiency for MicroPort Endovascular MedTech Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of MicroPort Endovascular MedTech Ltd from 2016 to 2025. Review 688016 cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥8.62 Billion ≈ $1.26 Billion |
CN¥573.06 Million ≈ $83.86 Million |
0.066x | -32.01% |
| 2024-12-31 | CN¥3.82 Billion ≈ $559.35 Million |
CN¥373.60 Million ≈ $54.67 Million |
0.098x | -33.89% |
| 2023-12-31 | CN¥3.86 Billion ≈ $565.36 Million |
CN¥571.22 Million ≈ $83.59 Million |
0.148x | -22.81% |
| 2022-12-31 | CN¥1.74 Billion ≈ $255.00 Million |
CN¥333.76 Million ≈ $48.84 Million |
0.192x | -2.91% |
| 2021-12-31 | CN¥1.52 Billion ≈ $222.73 Million |
CN¥300.25 Million ≈ $43.94 Million |
0.197x | +11.95% |
| 2020-12-31 | CN¥1.23 Billion ≈ $180.57 Million |
CN¥217.44 Million ≈ $31.82 Million |
0.176x | +31.17% |
| 2019-12-31 | CN¥1.07 Billion ≈ $155.98 Million |
CN¥143.20 Million ≈ $20.96 Million |
0.134x | -72.82% |
| 2018-12-31 | CN¥216.16 Million ≈ $31.63 Million |
CN¥106.85 Million ≈ $15.64 Million |
0.494x | +34.01% |
| 2017-12-31 | CN¥188.02 Million ≈ $27.51 Million |
CN¥69.36 Million ≈ $10.15 Million |
0.369x | +51.03% |
| 2016-12-31 | CN¥123.38 Million ≈ $18.05 Million |
CN¥30.13 Million ≈ $4.41 Million |
0.244x | -- |
About MicroPort Endovascular MedTech Ltd
Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, manufacturing, sale, and services of aortic, peripheral vascular, and tumor intervention devices in China and internationally. The company offers Fontus, a branched stent graft system in surgical operation; CRONUS, a stent graft system in surgical operation; Hector, a multi-branch thoracic stent graft syste… Read more